Effect of continuous deep sedation on survival in the last days of life of cancer patients: A multicenter prospective cohort study

Background: Continuous deep sedation is ethically controversial with respect to whether it shortens a patient’s life. Aim: To examine whether continuous deep sedation shortens patient survival from the day of Palliative Performance Scale decline to 20 (PPS20). Design: A part of a multicenter prospective cohort study (EASED study). Setting/participants: We recruited consecutive adult patients with advanced cancer admitted to 23 participating palliative care units in 2017 in Japan. We compared survival from PPS20 between those who did and did not receive continuous deep sedation. Continuous deep sedation was defined as the continuous administration of sedative medication with the intention to keep a patient continuously unconscious to alleviate otherwise uncontrollable symptoms, but the dose of sedatives was adjusted to achieve adequate symptom relief for each patient. The propensity score-weighting method was used to control for potential confounders, and five sensitivity analyses were performed. Results: A total of 1926 patients were enrolled. Patients discharged alive were excluded, and we analyzed 1625 patients of whom 156 (9.6%) received continuous deep sedation. Median survival from PPS20 of 1625 patients was 81 h (95% CI: 77–88). The RASS scores decreased to ⩽−4 was 66% at 24 h. Continuous deep sedation was not associated with a significant survival risk (adjusted hazard ratio: 1.06, 95% CI: 0.85–1.33). All sensitivity analyses, including continuous deep sedation defined as the RASS score was ⩽−4 achieved the essentially the same results. Conclusions: Continuous deep sedation with careful dose adjustment was not associated with shorter survival in the last days of life in patients with advanced cancer.

[1]  H. Ahn,et al.  Association between continuous deep sedation and survival time in terminally ill cancer patients , 2020, Supportive Care in Cancer.

[2]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[3]  I. Higginson,et al.  A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS) , 2019, Palliative medicine.

[4]  R. Twycross Reflections on palliative sedation , 2019, Palliative care.

[5]  E. Matsushima,et al.  Validation of the Integrated Palliative care Outcome Scale (IPOS) – Japanese Version , 2019, Japanese journal of clinical oncology.

[6]  A. Takeuchi,et al.  A combination of routine laboratory findings and vital signs can predict survival of advanced cancer patients without physician evaluation: a fractional polynomial model. , 2018, European journal of cancer.

[7]  T. Morita,et al.  Efficacy of two types of palliative sedation therapy defined using intervention protocols: proportional vs. deep sedation , 2018, Supportive Care in Cancer.

[8]  J. Verheijde,et al.  Uniformly defining continuous deep sedation. , 2016, The Lancet. Oncology.

[9]  C. Blinderman,et al.  Comfort Care for Patients Dying in the Hospital. , 2015, The New England journal of medicine.

[10]  E. Bruera,et al.  A diagnostic model for impending death in cancer patients: Preliminary report , 2015, Cancer.

[11]  I. Higginson,et al.  Discovering the hidden benefits of cognitive interviewing in two languages: The first phase of a validation study of the Integrated Palliative care Outcome Scale , 2015, Palliative medicine.

[12]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[13]  I. Kiesewetter,et al.  Medication and monitoring in palliative sedation therapy: a systematic review and quality assessment of published guidelines. , 2015, Journal of pain and symptom management.

[14]  G. Mitchell,et al.  Palliative pharmacological sedation for terminally ill adults. , 2015, The Cochrane database of systematic reviews.

[15]  N. Cherny,et al.  ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Brearley,et al.  Current debates on end-of-life sedation: an international expert elicitation study , 2014, Supportive Care in Cancer.

[17]  S. Brearley,et al.  From sedation to continuous sedation until death: how has the conceptual basis of sedation in end-of-life care changed over time? , 2013, Journal of pain and symptom management.

[18]  Jason Boland Articles of interest in other scholarly journals , 2013, BMJ Supportive & Palliative Care.

[19]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[20]  S. Brearley,et al.  Continuous sedation (CS) until death: mapping the literature by bibliometric analysis. , 2013, Journal of pain and symptom management.

[21]  C. Earle,et al.  Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. White,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[23]  L. Radbruch,et al.  Sedierung in der Palliativmedizin – Leitlinie1 für den Einsatz sedierender Maßnahmen in der Palliativversorgung , 2010 .

[24]  B. Lo,et al.  Last-Resort Options for Palliative Sedation , 2009, Annals of Internal Medicine.

[25]  M. Maltoni,et al.  Palliative sedation therapy does not hasten death: results from a prospective multicenter study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  L. J. Materstvedt,et al.  Deep and continuous palliative sedation (terminal sedation): clinical-ethical and philosophical aspects. , 2009, The Lancet. Oncology.

[27]  J. Legemaate,et al.  A national guideline for palliative sedation in the Netherlands. , 2007, Journal of pain and symptom management.

[28]  T. Morita,et al.  Development of a clinical guideline for palliative sedation therapy using the Delphi method. , 2005, Journal of palliative medicine.

[29]  T. Morita,et al.  Family experience with palliative sedation therapy for terminally ill cancer patients. , 2004, Journal of pain and symptom management.

[30]  N. Sykes,et al.  Sedative use in the last week of life and the implications for end-of-life decision making. , 2003, Archives of internal medicine.

[31]  C. Sessler,et al.  The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. , 2002, American journal of respiratory and critical care medicine.

[32]  Mark J. Smith,et al.  The Memorial Delirium Assessment Scale. , 1997, Journal of pain and symptom management.

[33]  T. Morita,et al.  Continuous Deep Sedation: A Proposal for Performing More Rigorous Empirical Research. , 2017, Journal of pain and symptom management.

[34]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[35]  C. Takigawa,et al.  Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. , 2016, The Lancet. Oncology.

[36]  達也 森田,et al.  緩和ケア用Richmond Agitation-Sedation Scale (RASS)日本語版の作成と言語的妥当性の検討 , 2016 .

[37]  C. Takigawa,et al.  Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. , 2005, Journal of Pain and Symptom Management.

[38]  G. Shaw,et al.  Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .